|
|
FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. NASDAQ:NEO the "Company", a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The initial determination is that... Lire le communiqué |
|
| |
|
| |
|
|
FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. NASDAQ:NEO, a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease MRD will be presented at the 46th annual San Antonio Breast Cancer Symposium SABCS.... Lire le communiqué |
|
| |
|
| |
|
|
FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. NASDAQ:NEO, a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.Members of NeoGenomics management team will participate in a fireside chat on Wednesday, November 29th at 9:00 a.m. Eastern Time. A live and... Lire le communiqué |
|
| |
|
| |
|
|
Third Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. NASDAQ:NEO the "Company", a leading oncology testing services company, today announced its thirdquarter results for the period ended September 30, 2023 as compared to September 30, 2022.Third Quarter 2023 HighlightsQ3 2023 Res... Lire le communiqué |
|
| |
|
| |
|
|
Neo Comprehensive™ Heme Cancers is a large and comprehensive nextgeneration sequencing panel with broad coverage of genes associated with blood cancersEarlystage NSCLC Panel a therapy selection panel providing a comprehensive overview of biomarkers for detecting earlystage lung cancerFT. MYERS, FL / ACCESSWIRE / October 24, 2023 / NeoGenomics, Inc. NASDAQ:NEO, a leading oncology testing... Lire le communiqué |
|
| |
|
| |
|
|
FT. MYERS, FL / ACCESSWIRE / October 17, 2023 / NeoGenomics, Inc. NASDAQ:NEO, a leading provider of oncology testing and global contract research services, today announced that it will report its third quarter 2023 financial results on Monday, November 6, 2023. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent... Lire le communiqué |
|
| |
|
| |
|
|
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomesFT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancerfocused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited "Inivata" has announced the... Lire le communiqué |
|
| |
|
| |
